RaySearch Laboratories AB (publ)
STO:RAY B

Watchlist Manager
RaySearch Laboratories AB (publ) Logo
RaySearch Laboratories AB (publ)
STO:RAY B
Watchlist
Price: 204 SEK -0.49% Market Closed
Market Cap: 7B SEK
Have any thoughts about
RaySearch Laboratories AB (publ)?
Write Note

Net Margin
RaySearch Laboratories AB (publ)

15%
Current
3%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
15%
=
Net Income
175.1m
/
Revenue
1.2B

Net Margin Across Competitors

Country SE
Market Cap 7B SEK
Net Margin
15%
Country US
Market Cap 36.3B USD
Net Margin
25%
Country US
Market Cap 31.3B USD
Net Margin
10%
Country AU
Market Cap 26.6B AUD
Net Margin
50%
Country US
Market Cap 10.8B USD
Net Margin
34%
Country US
Market Cap 6.3B USD
Net Margin
-6%
Country JP
Market Cap 927.2B JPY
Net Margin
16%
Country US
Market Cap 5.6B USD
Net Margin
4%
Country SE
Market Cap 52.8B SEK
Net Margin
25%
Country US
Market Cap 2.4B EUR
Net Margin
-4%
Country CN
Market Cap 16.7B CNY
Net Margin
11%
No Stocks Found

RaySearch Laboratories AB (publ)
Glance View

Market Cap
7B SEK
Industry
Health Care

RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. The company is headquartered in Stockholm, Stockholm. The company markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.

RAY B Intrinsic Value
219.97 SEK
Undervaluation 7%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
15%
=
Net Income
175.1m
/
Revenue
1.2B
What is the Net Margin of RaySearch Laboratories AB (publ)?

Based on RaySearch Laboratories AB (publ)'s most recent financial statements, the company has Net Margin of 15%.